Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,930.06
(
-0.09%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
90.68
(
-2.14%
)
Bitcoin
75,761.91
(
2.57%
)
News Focus
News Focus
Post# of 257431
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: mcbio post# 148047

Friday, 08/31/2012 10:00:00 PM

Friday, August 31, 2012 10:00:00 PM

Post# of 257431

ASTX's pipeline identifies the BACE inhibitor partnered with AZN as AZD3293 (astx.com/pipeline/products/preclinical#azdxxxx ) and it appears to be pre-clinical. Was AZD3839 shelved, re-named, or what?

Did some Googling and found my answer in an Edison Investment Research report dated 7/26/12. After Phase 1 studies, AZD3839 was dropped in favor of AZD3293, which is now in pre-clinical studies.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today